Insider Transactions in Q2 2021 at Collegium Pharmaceutical, Inc (COLL)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 02
2021
|
Joseph Ciaffoni President and CEO |
SELL
Open market or private sale
|
Direct |
5,861
-2.14%
|
$128,942
$22.81 P/Share
|
|
Jun 01
2021
|
Joseph Ciaffoni President and CEO |
SELL
Open market or private sale
|
Direct |
16,205
-2.83%
|
$372,715
$23.13 P/Share
|
|
Jun 01
2021
|
Joseph Ciaffoni President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
16,205
+5.3%
|
$129,640
$8.22 P/Share
|
|
Jun 01
2021
|
Joseph Ciaffoni President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,672
-1.68%
|
$102,784
$22.9 P/Share
|
|
May 24
2021
|
Colleen Tupper EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
42,000
+50.0%
|
-
|
|
May 20
2021
|
Garen G Bohlin Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,941
+32.18%
|
-
|
|
May 20
2021
|
Gwen A Melincoff Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,941
+32.18%
|
-
|
|
May 20
2021
|
Gino Santini Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,941
+18.38%
|
-
|
|
May 20
2021
|
Michael Thomas Heffernan Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,941
+41.54%
|
-
|
|
May 20
2021
|
John A. Fallon Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,941
+29.89%
|
-
|
|
May 20
2021
|
Rita J. Balice Gordon Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,941
+39.91%
|
-
|
|
May 20
2021
|
John Gordon Freund Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,941
+32.18%
|
-
|
|
May 10
2021
|
Shirley R. Kuhlmann EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
7,000
-7.22%
|
$154,000
$22.77 P/Share
|
|
Apr 01
2021
|
Alison B Fleming EVP & Chief Technical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,657
-3.15%
|
$222,111
$23.38 P/Share
|
|
Apr 01
2021
|
Richard Malamut EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,119
-3.23%
|
$71,737
$23.38 P/Share
|